T 0254/17 03-08-2018

1. In the present case, the appellant did not comment on the auxiliary requests filed in response to the statement setting out the grounds of appeal, even though auxiliary request 1 ultimately formed the basis for the main request filed at the oral proceedings ("New MR"). The appellant also withdrew its request for oral proceedings and was not represented at the oral proceedings before the board. Accordingly, in the present decision the board will primarily deal with the appellant's original requests and arguments, in so far as they are applicable to the current main request (Article 15(3) RPBA).

2. Admission of documents

2.1 Documents D11 to D15 were filed only a few days prior to the oral proceedings before the opposition division. The admission of documents filed after the nine-month time limit for opposition is at the discretion of the opposition division. It is evident from the appealed decision that the opposition division examined whether the documents were prima facie relevant, both for assessing novelty and inventive step. The board cannot identify any error in the discretionary decision of the opposition division and sees no reason to reverse it. Therefore, these documents are not part of the present proceedings.

2.2 D17 and D18 were filed on appeal to further support the admissibility of documents D11 to D15. Since the latter documents were not admitted into the proceedings, the board sees no reason to admit D17 and D18.

3. Added subject-matter

3.1 The opposed patent is based on the application as filed, which is a European divisional patent application filed in respect of the earlier European patent application No. 04 255 726 (parent application). The two applications have an identical description. In the following discussion of added subject-matter, reference will be made only to the application as filed, it being understood that the same disclosure is present also in the parent application as filed.

3.2 The basis for the subject-matter of claim 1 can be found on page 3, lines 11 to 14, of the application as filed, which reads: "The present invention also provides a method for slowing the progression of weight loss beyond an elderly pets' [sic] ideal body weight by administering to the pet a composition comprising one or more antioxidants, an oil blend including linoleic acid, and a prebiotic." The elderly pet described throughout the application is an elderly cat (e.g. page 1, lines 4 and 5; page 4, lines 10 to 13; and the example, page 9, line 11 onwards, which relates to a long-term study on senior cats). Further, the oils high in omega 3 and omega 6 are described as preferred for all compositions of the invention. Support for these oils can be found on page 2, lines 17 and 18 of the application as filed. These oils are also used in the composition of diet 3 of the example, which corresponds to the composition recited in claim 1. In other words, for the skilled person the combination of the features of claim 1 is directly and unambiguously derivable from the application as filed.

3.3 The appellant objected to the introduction of the term "source" into claim 1 ("source of antioxidants" and "source of prebiotic"). However, it has not explained why, in its view, this amendment adds subject-matter. Moreover, "source of antioxidants" is explicitly disclosed on page 4, line 22, and "source of prebiotic" on page 2, line 10.

3.4 Furthermore, it raised a general objection that the subject-matter of the dependent claims was not disclosed in combination with the subject-matter of claim 1. The board does not agree. The subject-matter of claims 2 to 9 relates to the preferred ingredients and form of the composition disclosed in the application as filed. The combination of these features is in particular pointed to by the (inventive) diet 3 of the example.

3.5 In view of these considerations, claims 1 to 9 do not include added subject-matter and so comply with the requirements of Article 123(2) EPC and of Article 76(1), second sentence, EPC.

4. Sufficiency of disclosure

4.1 The appellant argued that the composition disclosed in claim 1 of the patent as granted did not provide any effect relating to weight management. Although this objection was not raised in the context of the present main request, the board considers that the objection carried over to claim 1 of the main request, which is directed to a more specific weight-management effect, namely the slowing of the progression of weight loss beyond an elderly cat's ideal body weight.

4.2 In the example of the opposed patent (paragraph [0046] onwards) elderly cats were assigned to three different test groups. Each test group received a different diet:

- diet 1 (standard fish-based cat food);

- diet 2 (standard fish-based cat food including antioxidants); and

- diet 3 (standard fish-based cat food including antioxidants, namely beta-carotene and vitamin E, an oil blend including omega 3 and omega 6 fatty acids and chicory root, a source of prebiotics).

The composition of diet 3 corresponds to the composition of claim 1. The effects of these diets are discussed in paragraph [0049] onwards. Weight maintenance is discussed in paragraph [0056] of the opposed patent. The first two sentences of this paragraph read: "All three groups lost weight over time, on average, which is expected with aging cats. Average weight losses and food consumption were not significantly different between the three dietary treatment groups." At first glance this statement appears to confirm the appellant's argument that the patent itself demonstrates that the claimed effect is not achieved. However, the board agrees with the respondent that this statement has to be read in the context of the example as a whole. In the same paragraph, the diet compositions are compared with regard to the microflora and the blood values, in particular plasma linoleic acid. Positive effects are identified for the composition of diet 3, as compared with the effects achieved with diet 1 or diet 2.

4.3 Thus, the skilled person would understand from the entire paragraph that the slowing of the progression of weight loss had not yet been fully confirmed, but that this effect was nevertheless expected, in view of the other positive results identified in the patent, such as the pathology results (paragraph [0054]), the microflora (paragraph [0056], lines 6 to 10), the plasma linoleic acid (paragraph [0056], lines 11 and 12 and on table 7), the antioxidant status and intestinal health (paragraph [0061]). All these effects would ultimately contribute to slowing the progression of weight loss. The respondent's argument is technically sound and the board is not aware of any argument which might speak against it. Therefore, the board concludes that the (prophylactic) therapeutic effect of slowing the progression of weight loss beyond an elderly cat's ideal body weight is sufficiently disclosed.

4.4 This effect was confirmed in D10, a post-published study. It describes, inter alia, that senior cats fed with a diet which corresponds to the composition described in claim 1 are subject to less decrease in body weight than cats fed with reference diets (D10, page 40, right column, last paragraph; and figure 5). In this context, it is worth noting that the post-published evidence D10 is only supplementary and does not serve as the sole basis for establishing that the claimed effect of slowing the progression of weight loss is indeed achieved. As mentioned above, not only was the claimed effect asserted in the application as filed, it was also shown to be at least plausible by the disclosure of the application as filed, and D10 is not the first disclosure going beyond speculation (by analogy with T 1329/04, point 12).

4.5 In view of these considerations, the ground of Article 100(b) EPC does not prejudices the maintenance of the patent on the basis of the main request.

5. Novelty and inventive step

5.1 The appellant's arguments regarding lack of novelty and lack of inventive step were based on the assumption that a therapeutic treatment is neither plausible nor achieved. As discussed above in the context of the assessment of sufficiency of disclosure, the board does not agree with this interpretation. Consequently, the appellant's novelty and inventive step attacks must be regarded as flawed from the outset.

5.2 Claim 1 is a second medical use claim in the Swiss-type form. The novelty of the subject-matter of such a claim can be derived from the new therapeutic application (Case Law of the Boards of Appeal of the EPO, 8th edition 2016, Chapter I.C.7.2.1). The board is not aware of any prior-art document disclosing a composition such as that recited in claim 1 and discussing the required specific therapeutic application.

5.3 Thus, D1 discloses a functional cocktail for a senior pet diet including flaxseed oil (an oil high in omega 3) and sunflower oil (which is rich in linoleic acid, an omega 6 fatty acid), vitamin E (an antioxidant) and chicory (a source of prebiotic), but it does not disclose the therapeutic application recited in claim 1. Similar considerations apply to D2, which discloses a cat food composition called "Felidae": the composition contains the ingredients of the claimed composition, but the specific therapeutic use is not disclosed. Thus, the board concludes that the subject-matter of claim 1 is novel over the cited prior art (Article 54 EPC).

5.4 The appellant also raised novelty objections based on D6 (the publication of the parent application) and D10 (post-published evidence) "in the event that the opposed patent is denied divisional status". However, in view of the conclusions drawn above (see point 3.5), the board does not consider D6 and D10 to be prior art, and the appellant's objections of lack of novelty based on these two documents must fail.

5.5 With regard to inventive step, the appellant considered that there were a number of equally suitable candidates for selection as the closest prior art. In this context, it discussed documents D1, D2, D3, D4 and D5. The board considers that it is not crucial which document is selected as the closest prior art, because none of the cited documents describes the therapeutic application recited in claim 1. Thus, the functional cocktail suitable for senior pets described in paragraph [0015] of D1 may well be considered the closest prior art, while the therapeutic application is the distinguishing feature.

5.6 The objective technical problem in view of D1 has to be seen in the provision of a further (medical) use of the composition of D1. As apparent from the discussion relating to sufficiency of disclosure, this problem is plausibly solved, namely by the use of the composition in slowing the progression of weight loss beyond an elderly cat's ideal body weight.

5.7 There was nothing indicating this solution to the skilled person in D1 itself or in any other cited prior art. In view of this, the board concludes that the subject-matter of claim 1 involves an inventive step (Article 56 EPC).

6. Since the main request is allowable, there is no need to deal with the auxiliary requests.